18,124 results on '"Cyclooxygenase Inhibitors"'
Search Results
402. Cyclooxygenase inhibitors combined with deuterium-enriched water augment cytotoxicity in A549 lung cancer cell line via activation of apoptosis and MAPK pathways.
- Author
-
Hassanzade, Abdolreza, Mandegary, Ali, Sharif, Elham, Rasooli, Rokhsana, Mohammadnejad, Reza, and Masoumi-Ardekani, Yaser
- Subjects
- *
LUNG cancer , *CYCLOOXYGENASE inhibitors , *CELL-mediated cytotoxicity , *CANCER chemotherapy , *DRUG side effects , *CANCER cells , *DEUTERIUM - Abstract
Objective(s): Combination chemotherapy is a rational strategy to increase patient response and tolerability and to decrease adverse effects and drug resistance. Recently, the use of non-steroidal anti-inflammatory drugs (NSAIDs) has been reported to be associated with reduction in occurrence of a variety of cancers including lung cancer. On the other hand, growing evidences suggest that deuterium-enriched water (DEW, D2O) and deuterium-depleted water (DDW) play a role both in treatment and prevention of cancers. In the present study, we examined the effects of DEW and DDW in combination with two NSAIDs, celecoxib and indomethacin, on A549 human non-small lung cancer cell to identify novel treatment options. Materials and. Materials and Methods: The cytotoxicity of celecoxib or indomethacin, alone and in combination with DDW and DEW was determined. The COX-2, MAPK pathway proteins, the anti-apoptotic Bcl2 and pro-apoptotic Bax proteins and caspase-3 activity were studied for cytotoxic combinations. Results: Co-administration of selective and non-selective COX-2 inhibitors with DEW led to a remarkable increase in cytotoxicity and apoptosis of A549 cells. These events were associated with activation of p38 and JNK MAPKs and decreasing pro-survival proteins Bcl-2, COX-2 and ERK1/2. Furthermore, the combination therapy activated caspase-3, and the apoptosis mediator, and disabled poly ADP-ribose polymerase (PARP), the key DNA repair enzyme, by cleaving it. Conclusion: The combination of DEW with NSAIDs might be effective against lung cancer cells by influence on principal cell signalling pathways, and this has a potential to become a candidate for chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
403. Randomized open-labbel non-inferiority trial of acetaminophen or loxoprofen for patients with acute low back pain.
- Author
-
Miki, Kenji, Ikemoto, Tatsunori, Hayashi, Kazuhiro, Arai, Young-Chang, Ushida, Takahiro, Sekiguchi, Miho, and Shi, Kenrin
- Subjects
- *
ACETAMINOPHEN , *TREATMENT of backaches , *NONSTEROIDAL anti-inflammatory agents , *ANALGESICS , *CYCLOOXYGENASE inhibitors , *ANALGESIA , *ASPARTATE aminotransferase - Abstract
Background Current worldwide clinical practice guidelines recommend acetaminophen as the first option for the treatment of acute low back pain. However, there is no concrete evidence regarding whether acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) is more effective for treating acute low back pain (LBP) in Japan. The present study aimed to investigate whether acetaminophen treatment for acute musculoskeletal pain was comparable with loxoprofen (a traditional NSAID in Japan) treatment. Methods Of the 140 patients with acute LBP who visited out-patient hospitals, 127 were considered eligible and were randomly allocated to a group taking acetaminophen or one taking loxoprofen. As primary outcome measure, pain intensity was measured using a 0–10-numeric rating scale (NRS). Moreover, pain disability, pain catastrophizing, anxiety, depression, and quality of life, as well as adverse events, were assessed as secondary outcomes. The primary outcome was tested with a noninferiority margin (0.84 on changes in pain-NRS), and the secondary outcomes were compared using conventional statistical methods at week 2 and week 4. Results Seventy patients completed the study (acetaminophen: 35, loxoprofen: 35). The dropout rates showed no significant difference between the two medication-groups. We found that the mean differences of changes in pain-NRS from baseline to week 2 or 4 between the two medication groups were not statistically beyond the noninferiority margin (mean [95% confidence interval]: −0.51 [−1.70, 0.67], at week 2 and −0.80 [−2.08, 0.48] at week 4). There were no consistent differences between the two medication groups in terms of secondary outcomes. Conclusions The results suggest that acetaminophen has comparable analgesic effects on acute LBP, based on at least a noninferiority margin, compared with loxoprofen at 4 weeks. Acetaminophen seems to be a reasonable first-line option for patients with acute LBP in Japan. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
404. Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq.
- Author
-
Maeda, Shingo, Tomiyasu, Hirotaka, Tsuboi, Masaya, Inoue, Akiko, Ishihara, Genki, Uchikai, Takao, Chambers, James K., Uchida, Kazuyuki, Yonezawa, Tomohiro, and Matsuki, Naoaki
- Subjects
- *
BLADDER cancer prevention , *RNA sequencing , *GENE expression , *PROSTAGLANDIN receptors , *CYCLOOXYGENASE inhibitors - Abstract
Background: Invasive urothelial carcinoma (iUC) is a major cause of death in humans, and approximately 165,000 individuals succumb to this cancer annually worldwide. Comparative oncology using relevant animal models is necessary to improve our understanding of progression, diagnosis, and treatment of iUC. Companion canines are a preferred animal model of iUC due to spontaneous tumor development and similarity to human disease in terms of histopathology, metastatic behavior, and treatment response. However, the comprehensive molecular characterization of canine iUC is not well documented. In this study, we performed transcriptome analysis of tissue samples from canine iUC and normal bladders using an RNA sequencing (RNA-Seq) approach to identify key molecular pathways in canine iUC.Methods: Total RNA was extracted from bladder tissues of 11 dogs with iUC and five healthy dogs, and RNA-Seq was conducted. Ingenuity Pathway Analysis (IPA) was used to assign differentially expressed genes to known upstream regulators and functional networks.Results: Differential gene expression analysis of the RNA-Seq data revealed 2531 differentially expressed genes, comprising 1007 upregulated and 1524 downregulated genes, in canine iUC. IPA revealed that the most activated upstream regulator was PTGER2 (encoding the prostaglandin E2 receptor EP2), which is consistent with the therapeutic efficiency of cyclooxygenase inhibitors in canine iUC. Similar to human iUC, canine iUC exhibited upregulated ERBB2 and downregulated TP53 pathways. Biological functions associated with cancer, cell proliferation, and leukocyte migration were predicted to be activated, while muscle functions were predicted to be inhibited, indicating muscle-invasive tumor property.Conclusions: Our data confirmed similarities in gene expression patterns between canine and human iUC and identified potential therapeutic targets (PTGER2, ERBB2, CCND1, Vegf, and EGFR), suggesting the value of naturally occurring canine iUC as a relevant animal model for human iUC. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
405. Effect of cyclooxygenase‑2 inhibition on the development of post‑traumatic stress disorder in rats.
- Author
-
Wang, Mengyang, Duan, Faliang, Wu, Jinglei, Min, Qiang, Huang, Qiaochun, Luo, Ming, and He, Zhuqiang
- Subjects
- *
CYCLOOXYGENASE 2 , *CYCLOOXYGENASE inhibitors , *POST-traumatic stress disorder , *LABORATORY rats , *PROSTAGLANDINS , *THROMBOXANES , *IMMUNOHISTOCHEMISTRY , *TUMOR necrosis factors - Abstract
Post‑traumatic stress disorder (PTSD) is characterized by re‑experiencing of a traumatic event, avoidance of trauma‑associated stimulation, general changes in mood and cognition, and hyper arousal symptoms. Cyclooxygenase is involved in the production of prostaglandins and thromboxanes, and its inducible form cyclooxygenase‑2(COX‑2), an important mediator of cell injury in inflammation, is primarily expressed in leukocytes and brain cells. The present study investigated the expression of COX‑2 in the hippocampi of rats with PTSD and evaluated the effect of COX‑2 inhibition on PTSD. Adult male Wistar rats were randomly divided into three groups: Control (n=20), PTSD (n=20) and intervention group (PTSD+COX‑2 inhibitor treatment, n=20). The expression of COX‑2 was detected by immunohistochemistry, reverse transcription‑quantitative polymerase chain reaction and western blotting. Terminal deoxynucleotidyl transferase mediated dUTP nick end labeling staining was used to observe the apoptosis of rat hippocampal neurons. Tumor necrosis factor α (TNF‑α), interleukin (IL)‑6 and prostaglandin E2 (PGE2) levels were analyzed by ELISA. Nitric oxide (NO) was detected using the Griess test. The behavioral and cognitive function of rats in the PTSD group was significantly decreased compared with the control group, while the behavioral and cognitive function of rats in the intervention group were improved. The COX‑2 mRNA and protein expression levels in hippocampi of rats in the PTSD group were higher than in the control and intervention group. The apoptosis of hippocampus in rats with PTSD was significantly increased compared with the control group and following treatment with COX‑2 inhibitor, apoptosis was decreased. In addition, compared with the control group and intervention group, the levels of TNF‑α, IL‑6, PGE2 and NO in hippocampi of rats were increased in the PTSD group. The present study indicated that COX‑2 may be involved in the pathogenesis of PTSD, and inhibition of its expression serves a neuroprotective role in hippocampi of PTSD rats. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
406. Effect of nordihydroguaiaretic acid on spermatogenesis and fertility in rats.
- Author
-
Abbas, M. A., Badran, D., and Disi, A.
- Subjects
- *
CYCLOOXYGENASE inhibitors , *SPERMATOGENESIS , *FERTILITY , *ANDROGEN-binding proteins , *TRANSMISSION electron microscopy - Abstract
Summary: Nordihydroguaiaretic acid (NDGA) is a naturally occurring lignan with potent antioxidant activity. Currently, it is in clinical trials as anticancer agent. As there is no earlier report on the effect of NDGA on spermatogenesis and fertility, this study was designed to investigate this aspect. Administration of NDGA to rats for 60 days produced degenerative changes in testis but had no effect on sperm DNA integrity test and androgen receptor expression. Ultrastructural studies revealed loss of integrity of cells in seminiferous tubules, vacuolation and presence of apoptotic bodies. Derangement of the outer dense fibres was noted in some sperm flagella. Acrosome formation appears to be normal. About 13.7% of epididymal spermatozoa had deformations like short tail or rounded head. This may explain the lower fertility index in NDGA‐treated group. No external deformations in newborns were noted. In conclusion, NDGA may have adverse effects on spermatogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
407. Prediction of Therapeutic Response to Cyclooxygenase Inhibitors in Preterm Infants with Patent Ductus Arteriosus.
- Author
-
Hu, Yang, Jin, Hongfang, Jiang, Yi, and Du, Junbao
- Subjects
- *
PATENT ductus arteriosus , *CYCLOOXYGENASE inhibitors , *PROSTAGLANDINS , *FETAL growth retardation , *NEONATAL diseases , *DISEASE risk factors - Abstract
Patent ductus arteriosus (PDA) is a morbid condition commonly seen in premature infants. Cyclooxygenase (COX) inhibitors, such as indomethacin and ibuprofen, are often used for the treatment of PDA in preterm infants, and they work by reducing the production of prostaglandin. However, as observed in clinical practice, not all PDAs in preterm infants can be closed using COX inhibitors. Some studies have demonstrated that gestational age, birth weight, B-type natriuretic peptide (BNP), and ductal diameter can predict the therapeutic responsiveness to COX inhibitors. This paper reviews the factors that can predict successful closure of the PDA in preterm infants using indomethacin or ibuprofen and presents new opinions and recent findings on this topic, including the predictive roles of intrauterine growth restriction, timing of the treatment, and the importance of platelet count and arterial pH. We also discuss the prospects for future studies to improve the individualized therapy of PDA in premature neonates. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
408. Diclofenac sodium gel therapy as an alternative to actinic cheilitis.
- Author
-
Gonzaga, Amanda Katarinny Goes, de Oliveira, Patrícia Teixeira, da Silveira, Éricka Janine Dantas, Queiroz, Lélia Maria Guedes, and de Medeiros, Ana Miryam Costa
- Subjects
- *
DICLOFENAC , *CHEILITIS , *ULTRAVIOLET radiation , *PHARMACEUTICAL gels , *DRUG side effects , *THERAPEUTICS - Abstract
Objective: Actinic cheilitis (AC) is a potentially malignant lesion caused by prolonged exposure to ultraviolet light. The aim of this research was to analyze the efficacy of diclofenac sodium 3% gel in the treatment of this condition, through clinical follow-up.Methods: Thirty-one patients diagnosed with AC were instructed to perform a topical application of the gel three times a day for a period of 90 days. In each visit, a digital photography was obtained for verified progress and response to treatment. Two researchers evaluated all images after treatment was completed and assigned the following scores regarding clinical aspect of the lip: 1, complete improvement; 2, partial improvement; 3, no changes; 4, worsening of the clinical condition. In addition, the patients’ tolerability to the drug and their satisfaction after treatment were evaluated.Results: Twelve cases abandoned the treatment for reasons unrelated to the study. Ten participants showed total remission of all clinical features of the lesion and three had partial improvement of the characteristics. One participant presented worsening of clinical condition, and in five cases, treatment was discontinued due to development of mild adverse effects at the site of gel application. Regarding satisfaction analyses and tolerability to the drug, from 14 patients who completed treatment without adverse effects or complications, most agreed fully that they were satisfied with the therapy (
n = 11) and that the drug was not irritating to the mouth (n = 9). Patients are being monitored without clinical signs of recurrence and/or progression of the lesions.Conclusion: Topical application of the drug has provided a convenient and well tolerated in most cases.Clinical relevance: Diclofenac sodium gel (3%) may be a promising alternative for treatment of actinic cheilitis. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
409. Nanoliposomal delivery of cytosolic phospholipase A2 inhibitor arachidonyl trimethyl ketone for melanoma treatment.
- Author
-
Gowda, Raghavendra, Dinavahi, Saketh S., Iyer, Soumya, Banerjee, Shubhadeep, Neves, Rogerio I., Pameijer, Colette R., and Robertson, Gavin P.
- Subjects
MELANOMA treatment ,ENZYME inhibitors ,PHOSPHOLIPASE A2 ,CYCLOOXYGENASE inhibitors ,CELL proliferation ,DRUG delivery systems - Abstract
Drug resistance and toxicity are major limitations of cancer treatment and frequently occurs during melanoma therapy. Nanotechnology can decrease drug resistance by improving drug delivery, with limited toxicity. This study details the development of nanoparticles containing arachidonyl trifluoromethyl ketone (ATK), a cytosolic phospholipase A 2 inhibitor, which can inhibit multiple key pathways responsible for the development of recurrent resistant disease. Free ATK is toxic, limiting its efficacy as a therapeutic agent. Hence, a novel nanoliposomal delivery system called NanoATK was developed, which loads 61.7% of the compound and was stable at 4 o C for 12 weeks. The formulation decreased toxicity-enabling administration of higher doses, which was more effective at inhibiting melanoma cell growth compared to free-ATK. Mechanistically, NanoATK decreased cellular proliferation and triggered apoptosis to inhibit melanoma xenograft tumor growth without affecting animal weight. Functionally, it inhibited the cPLA 2 , AKT, and STAT3 pathways. Our results suggest the successful preclinical development of a unique nanoliposomal formulation containing ATK for the treatment of melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
410. Chlorinated cobalt alkyne complexes derived from acetylsalicylic acid as new specific antitumor agents.
- Author
-
Obermoser, Victoria, Baecker, Daniel, Schuster, Carina, Braun, Valentin, Gust, Ronald, and Kircher, Brigitte
- Subjects
- *
CYCLOOXYGENASE inhibitors , *COBALT compounds , *ANTINEOPLASTIC agents - Abstract
[(Prop-2-ynyl)-2-acetoxybenzoate]dicobalthexacarbonyl (Co-ASS), an organometallic derivative of the irreversible cyclooxygenase-1/2 (COX-1/2) inhibitor acetylsalicylic acid (ASS), demonstrated high growth-inhibitory potential against various tumor cell lines and inhibition of both COX isoenzymes. With the objective of increasing the selectivity for COX-2, we introduced a chlorine substituent in position 3, 4, 5, or 6 of the ASS moiety, respectively. Increased COX-2 selectivity is desirable as this isoenzyme is predominantly related to the development of cancer and abnormal tissue growth. The new compounds were investigated in comprehensive cellular biological assays to identify the impact of the chlorine substitution at the complex on COX-1/2 inhibition, antiproliferative activity, apoptosis, metabolic activity, cell-based COX inhibition, and cellular uptake. Chlorination distinctly reduced the effects at isolated COX-1 (about 25% inhibition at 10 μM; Co-ASS: 82.7%), while those at COX-2 remained almost unchanged (about 65% inhibition at 10 μM; Co-ASS: 78.5%). In cellular systems, with exception of the 6-Cl derivative, all compounds showed notable antitumor activity in COX-1/2 expressing tumor cells (HT-29 (IC50 = 1.5–2.7 μM), MDA-MB-231 (IC50 = 5.2–8.0 μM)), but were distinctly less active in the COX-1/2-negative MCF-7 breast cancer cell line (IC50 = 15.2–22.9 μM). All complexes possess high selectivity for tumor cells, because they did not influence the growth of the non-tumorigenic, human bone marrow stromal cell line HS-5. These findings clearly demonstrate that the interference with the COX-1/2 cascade contributes to the mode of anticancer action of the cobalt alkyne complexes. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
411. Parecoxib's effects on anastomotic and abdominal wound healing: a randomized Controlled trial.
- Author
-
Martinou, Eirini, Drakopoulou, Stamatoula, Aravidou, Eftychia, Sergentanis, Theodore, Kondi-Pafiti, Agathi, Argyra, Eriphyli, Voros, Dionysios, and Fragulidis, Georgios P.
- Subjects
- *
CYCLOOXYGENASE inhibitors , *GASTROINTESTINAL surgery , *INTRAPERITONEAL injections , *ABDOMINAL injuries , *NEOVASCULARIZATION - Abstract
Background Current evidence regarding the effects of selective cyclooxygenase inhibitors on gastrointestinal anastomoses is controversial. An experimental randomized control study was conducted in our institution to histopathologically evaluate the consequences of parecoxib, on intestinal and abdominal wound healing. Methods Twenty-four adult Wistar rats underwent laparotomy, ascending colon transection, and hand-sewn anastomosis. They were randomized to receive either parecoxib (0.5 mg/kg twice daily) or 0.9% normal saline by intraperitoneal injection postoperatively. Animals were euthanatized either on the third or the seventh postoperative day. Semiquantitative methods were used to evaluate both intestinal and abdominal wounds for inflammatory cell composition, angiogenesis, fibroblasts, granular tissue, collagen deposition, epithelization, and presence of necrosis, exudate, and abscess formation. Results are presented as (parecoxib: median [IQR] versus control: median [IQR], P -value). Results No macroscopic anastomotic leakage or wound dehiscence was observed. Intestinal anastomoses in the parecoxib group, showed significantly decreased epithelization (2 [1] versus 3 [1], [ P = 0.004]) and collagen deposition (2 [0] versus 3 [1], [ P = 0.041]). No difference was observed in angiogenesis (3 [1] versus 2.5 [1], [ P = 0.158]). Abdominal wall specimens appeared to demonstrate decreased epithelization (2 [2] versus 4 [0.5], [ P = 0.0004]) in the treatment group. No difference between the two groups was identified regarding collagen deposition (2.5 [1] versus 2 [0.5], [ P = 0.280]) and angiogenesis (2.5 [1] versus 2 [1], [ P = 0.633]). Necrosis was significantly more present in the parecoxib group in both specimen types, (3.5 [1] versus 2.5 [1], [ P = 0.017]) and (3 [1] versus 1 [0.5], [ P < 0.0001]). Conclusions The present study shows that despite the absence of clinical adverse effects, parecoxib can impair anastomotic and abdominal wound healing on a histopathological level. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
412. Role of Cyclooxygenase Inhibitors in Diminution of Dissimilar Stress-induced Depressive Behavior and Memory Impairment in Rats.
- Author
-
Perveen, Tahira, Emad, Shaista, Haider, Saida, Sadaf, Sana, Qadeer, Sara, Batool, Zehra, Sarfaraz, Yousra, and Sheikh, Sheeza
- Subjects
- *
COGNITIVE ability , *ANTI-inflammatory agents , *CYCLOOXYGENASE inhibitors , *GLUCOCORTICOIDS , *TREATMENT of neurodegeneration , *NEURAL transmission , *ETHYLENEDIAMINETETRAACETIC acid - Abstract
Memory functions can be considerably affected by various life events and stress has shown to be a chief regulator. Different stress patterns have distinct effects on the overall functioning of the brain. Stress provokes inflammation not only in the periphery but also in the brain. Neuroinflammation causes alterations in neuronal structure and function, which eventually progress to the development of neurodegenerative diseases. Inflammatory reactions are modulated through communication between the nervous, endocrine and immune systems. An excessive release of stress hormones and changes in the neurotransmission system may cause cognitive impairments. The present study investigated dissimilar stress-related memory deficits and their diminution by non-steroidal anti-inflammatory drugs (NSAIDs). Treatment with cyclooxygenase inhibitors, which inhibit prostaglandin synthesis, has enhanced memory functions in a number of neuroinflammatory states. In this study, rats were exposed to a series of dissimilar stressors and behavioral parameters for depression and memory functions were examined. Corticosterone, serotonin (5-HT) and dopamine (DA) levels were also estimated. Results from the forced swim test, elevated plus maze test and Morris water maze test showed significant effects of NSAIDs. A significant decrease in plasma corticosterone and increased DA and 5-HT levels were observed in NSAID-treated dissimilar-stressed rats. This study demonstrates the therapeutic potential of NSAIDs for dissimilar stress-induced depressive behaviors and impaired memory functions and related hormonal and neurochemical changes in the rat brain. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
413. Assessment of Platelet Function in Traumatic Brain Injury--A Retrospective Observational Study in the Neuro-Critical Care Setting.
- Author
-
Lindblad, Caroline, Thelin, Eric Peter, Nekludov, Michael, Frostell, Arvid, Nelson, David W., Svensson, Mikael, and Bellander, Bo-Michael
- Subjects
BRAIN injuries ,ARACHIDONIC acid - Abstract
Background: Despite seemingly functional coagulation, hemorrhagic lesion progression is a common and devastating condition following traumatic brain injury (TBI), stressing the need for new diagnostic techniques. Multiple electrode aggregometry (MEA) measures platelet function and could aid in coagulopathy assessment following TBI. The aims of this study were to evaluate MEA temporal dynamics, influence of concomitant therapy, and its capabilities to predict lesion progression and clinical outcome in a TBI cohort. Material and methods: Adult TBI patients in a neurointensive care unit that underwent MEA sampling were retrospectively included. MEA was sampled if the patient was treated with antiplatelet therapy, bled heavily during surgery, or had abnormal baseline coagulation values. We assessed platelet activation pathways involving the arachidonic acid receptor (ASPI), P2Y12 receptor, and thrombin receptor (TRAP). ASPI was the primary focus of analysis. If several samples were obtained, they were included. Retrospective data were extracted from hospital charts. Outcome variables were radiologic hemorrhagic progression and Glasgow Outcome Scale assessed prospectively at 12 months posttrauma. MEA levels were compared between patients on antiplatelet therapy. Linear mixed effect models and uni-/multivariable regression models were used to study longitudinal dynamics, hemorrhagic progression and outcome, respectively. results: In total, 178 patients were included (48% unfavorable outcome). ASPI levels increased from initially low values in a time-dependent fashion (p < 0.001). Patients on cyclooxygenase inhibitors demonstrated low ASPI levels (p < 0.001), while platelet transfusion increased them (p < 0.001). The first ASPI (p = 0.039) and TRAP (p = 0.009) were significant predictors of outcome, but not lesion progression, in univariate analyses. In multivariable analysis, MEA values were not independently correlated with outcome. conclusion: A general longitudinal trend of MEA is identified in this TBI cohort, even in patients without known antiplatelet therapies. Values appear also affected by platelet inhibitory treatment and by platelet transfusions. While significant in univariate models to predict outcome, MEA values did not independently correlate to outcome or lesion progression in multivariable analyses. Further prospective studies to monitor coagulation in TBI patients are warranted, in particular the interpretation of pathological MEA values in patients without antiplatelet therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
414. Echocardiographic assessment of patent ductus arteriosus in very low birthweight infants over time: prospective observational study.
- Author
-
Yum, Sook Kyung, Moon, Cheong-Jun, Youn, Young-Ah, Lee, Jae Young, and Sung, In Kyung
- Subjects
- *
PATENT ductus arteriosus , *BIRTH weight , *ECHOCARDIOGRAPHY , *INFANTS , *CYCLOOXYGENASE inhibitors , *THERAPEUTICS , *LOW birth weight , *BLOOD pressure , *DIAGNOSTIC imaging , *LONGITUDINAL method , *COMPUTERS in medicine , *RECEIVER operating characteristic curves - Abstract
Background: We aimed to determine the echocardiographic parameters that can predict the presence of patent ductus arteriosus (PDA) and haemodynamically significant ductus arteriosus (HSDA) at different time points.Methods: Echocardiogram was performed on postnatal days 3 and 7(D3-Echo and D7-Echo, respectively) in 71 very low birthweight infants with a median gestational age of 28.0 weeks. We first assessed the correlation between D3-Echo findings among infants with ductal patency and persistent ductal patency on D7-Echo. We subsequently assessed the correlation between D7-Echo findings and ultimate need for PDA treatment.Results: Forty-nine (69.0%) infants had ductal patency on D3-Echo, and 32(65.3%) of these had persistent PDA on D7-Echo. Twenty of the latter (62.5%) underwent PDA treatment at a median chronological age of 19 days. PDA treatment was significantly correlated with DA size and DA peak-systolic-to-end-diastolic velocity(S/D) ratio on D3- and D7-Echo. Receiver operating characteristic curve analysis revealed that DA size ≥2.040 mm and S/D ratio ≥2.016 had fair sensitivity, specificity, and predictive values for PDA treatment.Conclusion: The significance of different echocardiographic parameters associated with future ductal patency or HSDA depends on the time of assessment. DA size and S/D ratio on day 7 are two reliable indicators of the need for future PDA treatment. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
415. Participation of the anti-inflammatory and antioxidative activity of docosahexaenoic acid on indomethacin-induced gastric injury model.
- Author
-
Pineda-Peña, Elizabeth Arlen, Martínez-Pérez, Yoalli, Galicia-Moreno, Marina, Navarrete, Araceli, Segovia, José, Muriel, Pablo, Favari, Liliana, Castañeda-Hernández, Gilberto, and Chávez-Piña, Aracely Evangelina
- Subjects
- *
DOCOSAHEXAENOIC acid , *INDOMETHACIN , *NONSTEROIDAL anti-inflammatory agents , *CYCLOOXYGENASE inhibitors , *OXIDATIVE stress , *THERAPEUTICS - Abstract
Adverse gastrointestinal (GI) effects caused by nonsteroidal anti-inflammatory drugs (NSAIDs), including indomethacin, are recognized as the major limitation to their clinical use. NSAID-induced gastric damage is generated by cyclooxygenase inhibition, activation of inflammatory processes, and oxidative stress. Docosahexaenoic acid (DHA), an omega-3 polyunsaturated fatty acid, has shown gastroprotective effects; however, the molecular mechanisms underlying these effects have not been fully explained. As a result, the aim of this study was to examine DHA's anti-inflammatory and antioxidative actions in a mouse model of indomethacin-induced gastric injury. Oral administration of DHA (3, 10, 30, and 100 mg/kg) caused a reduction in indomethacin-induced gastric hemorrhagic lesions. We found that the gastroprotective effects of DHA treatment (100 mg/kg) were accompanied by decreases in several parameters: in leukocyte recruitment; gastric levels of myeloperoxidase; leukotriene B 4 ; intercellular adhesion molecule-1; tumor necrosis factor alpha; and nuclear translocation of nuclear factor-кB. Concurrently, we observed an improvement in antioxidant defenses produced by the increase in superoxide dismutase and glutathione activities but not catalase; in addition, a decrease in some oxidative damage markers such as malondialdehyde and carbonyl proteins in lipids and proteins was observed. Furthermore, resolvin D1 production and expression of free fatty acid receptor 4 were stimulated by DHA. Therefore, this study identified the antioxidant and anti-inflammatory actions of DHA as the main mechanisms involved in DHA's gastroprotective effects against indomethacin-induced gastric damage. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
416. Formulation and Evaluation of Etodolac Oral Disintegrating Tablets.
- Author
-
Sushma, Thalla, Priyadarshini, Arsham, and Yamsani, Shravan Kumar
- Subjects
- *
ETODOLAC , *DRUG tablets , *CYCLOOXYGENASE inhibitors , *DRUG solubility , *DRUG bioavailability - Abstract
Etodolac is a nonsteroidal anti-inflammatory drug, which result in inhibition of the enzyme cyclooxygenase (COX). The aim of this study is to formulate and evaluate oral disintegrating tablets (ODTs) of etodolac to achieve rapid dissolution, absorption and further improving the bioavailability of the drug. The oral disintegrating tablets were prepared by using Croscarmellose sodium, Sodium starch glycolate and Crospovidone by direct compression method. Taste masking was done by flavouring agents. Drug-polymer complex was then formulated into orally disintegrating tablets by direct compression by using different concentrations of superdisintegrants. Tablets were evaluated for weight variation, thickness, hardness, friability, drug content, in vitro disintegration time, wetting time, water absorption ratio, and in vitro dissolution studies. Total nine formulations were prepared (i.e. F1 to F9), out of which tablets with F9 formulation containing 9% crospovidone showed faster disintegration within 15.05 seconds. [ABSTRACT FROM AUTHOR]
- Published
- 2018
417. Cyclooxygenase-2 expression in the eyes of cats with and without uveitis.
- Author
-
Zhi Hui Sim, Pinard, Chantale L., Plattner, Brandon L., and Bienzle, Dorothee
- Subjects
- *
CYCLOOXYGENASE inhibitors , *CYCLOOXYGENASE genetics , *UVEITIS , *UVEITIS treatment , *CAT diseases , *VETERINARY medicine , *PROGNOSIS , *VETERINARY diagnosis - Abstract
OBJECTIVE To characterize the distribution and intensity of cyclooxygenase (COX)-2 expression in the eyes of cats with and without uveitis and to determine whether COX-2 expression is correlated with severity of inflammation. SAMPLES Archived ocular tissue specimens from 51 cats with and 10 cats without ocular disease. PROCEDURES Specimens from only I eye were evaluated for each cat. Specimens were stained with H&E stain or immunohistochemical stain for detection of COX-2 and reviewed. For each eye, the type, severity, and distribution of inflammation and the distribution and intensity of COX-2 expression were determined for the uvea and other ocular tissues. Correlation between COX-2 expression and inflammation severity was also assessed. RESULTS COX-2 was not expressed in any nondiseased eye. Of the 51 diseased eyes, 20 had histologic evidence of lymphocytic-plasmacytic uveitis, 13 had neutrophilic uveitis, 11 had diffuse iris melanoma with uveitis, and 7 had diffuse iris melanoma without uveitis. of the 44 eyes with uveitis, COX-2 was detected in the uvea of 16, including II eyes with lymphocytic-plasmacytic uveitis, 4 with neutrophilic uveitis, and I with diffuse iris melanoma-induced uveitis. Inflammation was severe, moderate, or mild in 10, 5, and I of those eyes, respectively. Cyclooxygenase-2 was detected in the cornea of 21 eyes with uveitis and I eye with diffuse iris melanoma without uveitis. Uveitis severity was positively correlated with COX-2 expression in both the uvea and cornea. CONCLUSIONS AND CLINICAL RELEVANCE Results suggested that COX-2 is an inflammatory mediator in feline uveitis but not diffuse iris melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
418. Role of group 2 innate lymphocytes in aspirin-exacerbated respiratory disease pathogenesis.
- Author
-
White, Andrew A. and Doherty, Taylor A.
- Subjects
INNATE lymphoid cells ,NASAL polyps ,ASTHMA ,SINUSITIS ,PHYSIOLOGICAL effects of aspirin ,PATHOLOGICAL physiology ,CYCLOOXYGENASE inhibitors ,PATIENTS - Abstract
Aspirin-exacerbated respiratory disease (AERD) is characterized by chronic eosinophilic nasal polyps, asthma, and airway reactions upon cyclooxygenase (COX) 1 inhibition. AERD is present in up to 7% of adult patients with asthma and the underlying pathogenesis remains largely elusive but prostaglandin D2, cysteinyl leukotrienes, mast cells, and type 2 cytokines are thought to contribute. A wealth of studies have recently implicated group 2 innate lymphoid cells (ILC2), a novel lineage-negative lymphocyte population that produces type 2 cytokines, in human allergic disease pathogenesis. Importantly, our recent work identified that ILC2s are recruited to the nasal mucosa of patients on AERD after COX-1 inhibitor administration. Here, we review the potential impact of ILC2s in the development and propagation of type 2 inflammation in AERD [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
419. Distinct oxylipin alterations in diverse models of cystic kidney diseases.
- Author
-
Monirujjaman, Md, Devassy, Jessay G., Yamaguchi, Tamio, Sidhu, Nikhil, Kugita, Masanori, Gabbs, Melissa, Nagao, Shizuko, Zhou, Jing, Ravandi, Amir, and Aukema, Harold M.
- Subjects
- *
CYSTIC kidney disease , *OXYLIPINS , *CYCLOOXYGENASE inhibitors , *LIPOXYGENASE genetics , *ADOLESCENT nephronophthisis , *CYTOCHROME P-450 , *PHYSIOLOGY - Abstract
Cystic kidney diseases are characterized by multiple renal cysts and are the leading cause of inherited renal disease. Oxylipins are bioactive lipids derived from fatty acids formed via cyclooxygenase, lipoxygenase and cytochrome P450 activity, and are important regulators of renal health and disease. Oxylipins are altered in nephronophthisis, a type of cystic kidney disease. To further investigate and to determine whether other cystic renal diseases share these abnormalities, a targeted lipidomic analysis of renal oxylipins was performed in orthologous models of autosomal dominant polycystic kidney disease 1 ( Mx1Cre + Pkd1 flox/flox mouse) and 2 ( Pkd2 ws25/− mouse), autosomal recessive polycystic kidney disease (PCK rat) and nephronophthisis ( jck/jck mouse). Kidney cyclooxygenase oxylipins were consistently higher in all diseased kidneys, even in very early stage disease. On the other hand, cytochrome P450 epoxygenase derived oxylipins were lower only in the autosomal recessive polycystic kidney disease and nephronophthisis models, while lipoxygenase and cytochrome P450 hydroxylase derived oxylipins were lower only in nephronophthisis. Sex effects on renal oxylipin alterations were observed but they did not always coincide with sex effects on disease. For oxylipins with sex effects, arachidonic acid derived oxylipins formed via cyclooxygenases and lipoxygenases were higher in females, while oxylipins from other fatty acids and via cytochrome P450 enzymes were higher in males. The consistent and unique patterns of oxylipin alterations in the different models indicates the importance of these bioactive lipids in cystic renal diseases, suggesting that pharmacological agents (e.g. cyclooxygenase inhibitors) may be useful in treating these disorders, for which effective treatment remains elusive. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
420. α-Spinasterol: a COX inhibitor and a transient receptor potential vanilloid 1 antagonist presents an antinociceptive effect in clinically relevant models of pain in mice.
- Author
-
Brusco, Indiara, Camponogara, Camila, Carvalho, Fabiano Barbosa, Schetinger, Maria Rosa Chitolina, Oliveira, Mauro Schneider, Trevisan, Gabriela, Ferreira, Juliano, and Oliveira, Sara Marchesan
- Subjects
- *
ANALGESICS , *CYCLOOXYGENASE inhibitors , *POSTOPERATIVE pain , *ALLODYNIA , *DRUG efficacy - Abstract
Background and Purpose: Postoperative pain is one of the most common manifestations of acute pain and is an important problem faced by patients after surgery. Moreover, neuronal trauma or chemotherapeutic treatment often causes neuropathic pain, which induces disabling and distressing symptoms. At present, treatments of both painful conditions are inadequate. α-Spinasterol, which is well characterized as a transient receptor potential vanilloid 1 antagonist, has anti-inflammatory, antioxidant and antinociceptive effects. Therefore, we investigated its antinociceptive potential on postoperative and neuropathic pain, as well as its effect on COX-1 and COX-2 activities.Experimental Approach: Nociceptive responses in a postoperative pain model (surgical incision-induced) or different neuropathic pain models (trauma or chemotherapy-induced) were investigated in mice.Key Results: Oral administration of α-spinasterol reduced postoperative pain, when given as a pre- (0.5 h before incision) or post-treatment (0.5 h after incision), and reduced cell infiltration in the injured tissue. α-Spinasterol also reduced the mechanical allodynia induced by partial sciatic nerve ligation and the mechanical and cold allodynia induced by paclitaxel. Moreover, α-spinasterol inhibited COX-1 and COX-2 enzyme activities without altering the body temperature of animals. Importantly, α-spinasterol did not alter spontaneous or forced locomotor activity. Furthermore, it did not cause gastric damage or liver and kidney changes, nor did it alter cell viability in the cerebral cortex and spinal cord slices of mice.Conclusion and Implications: α-Spinasterol is an effective and safe COX inhibitor with antinociceptive effects in postoperative and neuropathic pain models. Therefore, it is an interesting prototype for the development of novel analgesic drugs. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
421. Twice-Daily vs. Once-Daily Dosing with 0.075% Bromfenac in DuraSite: Outcomes from a 14-Day Phase 2 Study.
- Author
-
Trattler, William and Hosseini, Kamran
- Subjects
- *
BRODIFACOUM , *OPHTHALMIC drugs , *NONSTEROIDAL anti-inflammatory agents , *ANTERIOR chamber (Eye) , *CYCLOOXYGENASE inhibitors - Abstract
Introduction: Bromfenac is a well-known topical ophthalmic nonsteroidal anti-inflammatory drug (NSAID) that is commercialized in the USA and other regions of the world. A new formulation, 0.075% bromfenac in DuraSite®, was developed to treat postoperative inflammation and reduce pain in patients who have undergone cataract surgery. We hypothesized that efficacy and safety would be enhanced with twice-daily (BID) dosing compared to once-daily (QD) dosing. Methods: This was a multicenter, double-masked, comparative study in which 40 and 45 subjects were randomized to groups receiving BID dosing and QD dosing, respectively. Subjects self-instilled the study drug for 14 days postoperative and were followed for an additional 2-week evaluation phase. The primary efficacy endpoint was the proportion of subjects with an anterior chamber cell (ACC) grade of 0 at day 15. Results: A total of 45 subjects had cleared ACC (grade '0') at day 15, of whom 21 were in the BID group (52.5%) and 24 were in the QD group (53.5%). A secondary analysis found 7/40 (17.5%) subjects in the BID group and 10/45 (22.2%) subjects in the QD group achieved an ACC grade of 0 at day 8. There were more adverse events in the QD group ( n = 16) than in the BID group ( n = 12). Conclusion: Similar outcomes were observed for subjects using Bromfenac 0.075% in DuraSite® in the BID and QD dosing regimens for the treatment of post-cataract surgery inflammation. Trial registration: ClinicalTrials.gov identifier, NCT01190878. Funding: InSite Vision (now a division of Sun Pharma). [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
422. Aspirin as a COX inhibitor and anti-inflammatory drug in human skeletal muscle.
- Author
-
Ratchford, Stephen M., Lavin, Kaleen M., Perkins, Ryan K., Jemiolo, Bozena, Trappe, Scott W., and Trappe, Todd A.
- Subjects
ASPIRIN ,SKELETAL muscle physiology ,CYCLOOXYGENASE inhibitors ,ANTI-inflammatory agents ,DINOPROSTONE - Abstract
Although aspirin is one of the most common anti-inflammatory drugs in the world, the effect of aspirin on human skeletal muscle inflammation is almost completely unknown. This study examined the potential effects and related time course of an orally consumed aspirin dose on the inflammatory prostaglandin E2 (PGE2)/cyclooxygenase (COX) pathway in human skeletal muscle. Skeletal muscle biopsies were taken from the vastus lateralis of 10 healthy adults (5 male and 5 female, 25 ± 2 yr old) before (Pre) and 2, 4, and 24 h after (Post) a standard dose (975mg) of aspirin and partitioned for analysis of 1) in vivo PGE2 levels in resting skeletal muscle and 2) ex vivo skeletal muscle PGE2 production when stimulated with the COX substrate arachidonic acid (5 μM). PGE2 levels in vivo and PGE2 production ex vivo were generally unchanged at each time point after aspirin consumption. However, most individuals clearly showed suppression of PGE2, but at varying time points after aspirin consumption. When the maximum suppression after aspirin consumption was examined for each individual, independent of time, PGE2 levels in vivo (184 ± 17 and 104 ± 23pg/g wet wt at Pre and Post, respectively) and PGE2 production ex vivo (2.74 ± 0.17 and 2.09 ± 0.11pg·mg wet wt-1·min-1 at Pre and Post, respectively) were reduced (P < 0.05) by 44% and 24%, respectively. These results provide evidence that orally consumed aspirin can inhibit the COX pathway and reduce the inflammatory mediator PGE2 in human skeletal muscle. Findings from this study highlight the need to expand our knowledge regarding the potential role for aspirin regulation of the deleterious influence of inflammation on skeletal muscle health in aging and exercising individuals. NEW & NOTEWORTHY This study demonstrated that orally consumed aspirin can target the prostaglandin/cyclooxygenase pathway in human skeletal muscle. This pathway has been shown to regulate skeletal muscle metabolism and inflammation in aging and exercising individuals. Given the prevalence of aspirin consumption, these findings may have implications for skeletal muscle health in a large segment of the population. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
423. Virtual screening and biological evaluation of novel antipyretic compounds.
- Author
-
Froes, Thamires Quadros, Melo, Miriam C. C., Souza, Gloria E. P., Castilho, Marcelo Santos, and Soares, Denis M.
- Subjects
- *
ANTIPYRETICS , *CYCLOOXYGENASE inhibitors , *HYPOTHALAMUS , *CHEMOKINES , *PATIENTS , *CARDIOVASCULAR diseases , *IN vivo studies - Abstract
Due to the absence of safety of the antipyretics to patients with cardiovascular dysfunction, new targets to treat inflammation have been pursued. mPGES-1 is a promising target because its inhibition would not cause the side-effects related to COX inhibition. To identify novel inhibitors of mPGES-1, we developed a ligand-based pharmacophore model that differentiates true inhibitors from decoys and enlightens the structure-activity relationships for known mPGES-1 inhibitors. The model (four hydrophobic centers, two hydrogen bond acceptor and two hydrogen bond donor points) was employed to select lead-like compounds from ZINC database for in vivo evaluation. Among the 18 compounds selected, five inhibited the fever induced by LPS. The most potent compound (5-(4-fluorophenyl)-3-({6-methylimidazo[1,2-a]pyridin-2-yl}methyl)-2,3dihydro-1,3,4-oxadiazol-2-one) is active peripherally ( i.v.) or centrally ( i.c.v.) (82.18% and 112% reduction, respectively) and reduces (69.13%) hypothalamic PGE2 production, without significant COX-1/2 inhibition. In conclusion, our in silico approach leads to the selection of a compound that presents the chemical features to inhibit mPGES-1 and reduces fever induced by LPS. Furthermore, the in vivo and in vitro results support the hypothesis that its mechanism of action does not depend on COX inhibition. Hence, it can be considered a promising lead compound for antipyretic development, once it would not have the side-effects of COX-1/2 inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
424. In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in Health and Disease.
- Author
-
Giaretta, A, Rocca, B, Di Camillo, B, Toffolo, GM, and Patrono, C
- Subjects
PHYSIOLOGICAL effects of aspirin ,PLATELET aggregation inhibitors ,PHARMACODYNAMICS ,CYCLOOXYGENASE inhibitors ,THROMBOCYTOSIS ,MEGAKARYOCYTES ,THROMBOXANES ,THERAPEUTICS - Abstract
The influence of platelet turnover on cyclooxygenase (COX-1) inhibition by low-dose aspirin remains largely uncharacterized due to limited feasibility of studying aspirin pharmacodynamics in bone marrow precursors. We developed an in silico compartmental model describing the aspirin effects on COX-1 activity in a population of megakaryocytes (MK) and in peripheral platelets. Model parameters were inferred from the literature and calibrated using measurements of serum thromboxane B
2 (sTXB2 ), as proxy of COX-1 activity in peripheral platelets, in 17 healthy subjects and 24 patients with essential thrombocythemia (ET). The model reproduced well the average time-course of sTXB2 inhibition in healthy (accuracy = 10.4%), the reduced inhibition of sTXB2 observed in ET, and the effect of different dosing regimens. In conclusion, the in silico model accurately describes COX-1 inactivation by low-dose aspirin in MK and platelets in different clinical settings, and might help personalize aspirin regimens in conditions of altered megakaryopoiesis. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
425. Impact of Cyclooxygenase-2 1195 G-Carrier Genotype Associated with Intestinal Metaplasia and Endoscopic Findings Based on Kyoto Classification.
- Author
-
Kodaka, Yasuhiro, Futagami, Seiji, Tatsuguchi, Atsushi, Yamawaki, Hiroshi, Sato, Hitomi, Hashimoto, Satomi, Kawagoe, Tetsuro, Ueki, Nobue, Nagoya, Hiroyuki, Maruki, Yuuta, Miyake, Kazumasa, Gudis, Katya, Sakamoto, Choitsu, and Iwakiri, Katsuhiko
- Subjects
- *
CYCLOOXYGENASE genetics , *CYCLOOXYGENASE inhibitors , *METAPLASIA , *ETIOLOGY of diseases , *ENDOSCOPIC surgery , *TUMOR necrosis factor genetics , *THERAPEUTICS - Abstract
Background/Aims: We aimed to clarify whether cyclooxygenase-2 (COX-2) and microsomal prostaglandin E synthase-1 (mPGES-1) genotypes were associated with certain histological findings and endoscopical appearances based on Kyoto classification. Methods: We enrolled 285 Helicobacter pylori -infected gastritis patients. Genotypes of COX-2 1195, COX-2 1290, mPGES-1, interleukin-1β (IL-1β) 511 and tumour necrosis factor-α (TNF-α) 308 were analyzed. Genotyping was performed by polymerase chain reaction. Endoscopic appearances and histological assessment were determined by using Kyoto classification, operative link on gastritic intestinal metaplasia assessment and the updated Sydney system. Results: There was a significant (p = 0.027) relationship between the IL-1β 511 C-carrier and histological gastric inflammation in H. pylori -infected gastritis patients. There was a significant (p = 0.009) correlation between the COX-2 1195 G-carrier genotype and histological intestinal metaplasia in the gastric antrum of H. pylori -infected gastritis patients and gastric xanthoma (p = 0.027). The COX-2 1195 G-carrier genotype was also significantly (p = 0.038) associated with the score of endoscopic intestinal metaplasia based on Kyoto classification. The mPGES-1 genotype was significantly (p = 0.002) associated with endoscopic swelling of area. Conclusion: Our results suggest that in Japan, there exists a significant correlation between the COX-2 1195 G-carrier genotype and intestinal metaplasia in histological and endoscopic findings based on Kyoto classification in H. pylori -infected gastric mucosa. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
426. New 1,3,4-oxadiazole/oxime hybrids: Design, synthesis, anti-inflammatory, COX inhibitory activities and ulcerogenic liability.
- Author
-
Abd-Ellah, Heba S., Abdel-Aziz, Mohamed, Shoman, Mai E., Beshr, Eman A.M., Kaoud, TamerS., and Ahmed, Al-Shaimaa F.F.
- Subjects
- *
OXADIAZOLES , *OXIMES , *NITRIC oxide synthesis , *CYCLOOXYGENASE inhibitors , *NONSTEROIDAL anti-inflammatory agents , *ANTIOXIDANT analysis - Abstract
A series of new 1,3,4-oxadiazole/oxime hybrids were synthesized and designed as potent COX inhibitors. The prepared compounds were evaluated for their anti-inflammatory, antioxidant and ulcerogenic activities. The results indicated that the prepared compounds exhibited remarkable anti-inflammatory activity with (69.60–109.60% of indomethacin activity) after 4 h. In vitro COX inhibitory assay showed that compounds 6d and 7h are potent COX inhibitors with IC 50 of (1.10–0.94) and (2.30–5.00) µM on both COX-1 and COX-2 respectively. Compound 7h was found to inhibit both COXs non-competitively with K i values of 73 µM and 89 µM. Most of the tested compounds showed ulcer-free stomachs compared to indomethacin. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
427. Non-selective COX inhibitors impair memory formation and short-term but not long-term synaptic plasticity
- Author
-
Jafar Doostmohammadi, Mahyar Janahmadi, Negin Saeedi, Narges Hosseinmardi, Samira Choopani, Mahgol Darvishmolla, Soomaayeh Heysieattalab, and Masoumeh Gholami
- Subjects
Male ,0301 basic medicine ,Sodium Salicylate ,Metabolite ,Long-Term Potentiation ,Analgesic ,Spatial Learning ,Water maze ,Pharmacology ,Hippocampus ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,In vivo ,Animals ,Cyclooxygenase Inhibitors ,Rats, Wistar ,Maze Learning ,Sodium salicylate ,Spatial Memory ,Neuronal Plasticity ,Aspirin ,Dose-Response Relationship, Drug ,biology ,Long-term potentiation ,General Medicine ,Rats ,030104 developmental biology ,chemistry ,Synaptic plasticity ,biology.protein ,Cyclooxygenase ,030217 neurology & neurosurgery - Abstract
Cyclooxygenase (COX) plays a critical role in synaptic plasticity. Therefore, long-term administration of acetylsalicylic acid (ASA) and its main metabolite, salicylate, as a COX inhibitor may impair synaptic plasticity and subsequently memory formation. Although different studies have tried to explain the effects of ASA and sodium salicylate (SS) on learning and memory, the results are contradictory and the mechanisms are not exactly known. The present study was designed to investigate the effects of long-term low-dose (equivalent to prophylactic dose) and short-term high-dose (equivalent to analgesic dose) administration of ASA and SS respectively, on spatial learning and memory and hippocampal synaptic plasticity. Animals were treated with a low dose of ASA (2 mg/ml solvated in drinking water, 6 weeks) or a high dose of SS, a metabolite of ASA, (300 mg/kg, 3 days, twice-daily, i.p). Spatial memory and synaptic plasticity were assessed by water maze performance and in vivo field potential recording from CA1, respectively. Animals treated with ASA but not SS showed a significant increase in escape latency and distance moved. Furthermore, in the probe test, animals treated with both drugs spent less time in the target quadrant zone. The paired-pulse ratio (PPR) at 20-ms inter-pulse intervals (IPI) as an index of short-term plasticity in both treated groups was significantly higher than of the control group. Interestingly, none of the administered drugs affected long-term potentiation (LTP). These data suggested that long-term inhibition of COX disrupted memory acquisition and retrieval. Interestingly, cognitive impairments happened along with short-term but not long-term synaptic plasticity disturbance.
- Published
- 2021
428. Safety of topical interventions for the treatment of actinic keratosis
- Author
-
Anja Wessely, Elias A T Koch, Theresa Steeb, Carola Berking, and Markus V. Heppt
- Subjects
medicine.medical_specialty ,Skin Neoplasms ,Erythema ,Psychological intervention ,Ingenol mebutate ,Postmarketing surveillance ,Antineoplastic Agents ,Imiquimod ,030204 cardiovascular system & hematology ,Administration, Cutaneous ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Diclofenac ,medicine ,Humans ,Cyclooxygenase Inhibitors ,Pharmacology (medical) ,Adverse effect ,business.industry ,Actinic keratosis ,General Medicine ,medicine.disease ,Dermatology ,Keratosis, Actinic ,Photochemotherapy ,chemistry ,030220 oncology & carcinogenesis ,Carcinoma, Squamous Cell ,medicine.symptom ,business ,medicine.drug - Abstract
Introduction: Actinic keratosis (AK) are proliferations of atypical keratinocytes that may eventually progress to cutaneous squamous cell carcinoma. Therefore, AK requires consequent and early treatment. Areas covered: A variety of effective approaches is currently available for the clearance of AK. These interventions may be applied either in a lesion-directed or field-directed mode as AK can occur as single or multiple lesions. Field-directed approaches typically comprise topical drug-mediated interventions which aim at eliminating all visible lesions and also at clearing subclinical changes of the actinically damaged field. However, most treatment options are associated with local adverse events such as erythema, scaling, pain, and rarely with systemic symptoms. This expert review provides a comprehensive and up-to-date overview of the safety considerations of the commonly prescribed topical treatment agents cyclooxygenase inhibitors, 5-fluorouracil, imiquimod, ingenol mebutate, and photodynamic therapy. All these therapies have been proven efficient, yet they differ considerably regarding their safety profile. Expert opinion: In the future, safety concerns will relate to long-term and irreversible adverse drug events instead of application site reactions. In particular, the rate of treatment-associated non-melanoma skin cancers will increasingly come into focus and warrant investigation in postmarketing surveillance trials with a long-term follow-up.
- Published
- 2021
429. Assessment of the Effects of Cyclooxygenase Inhibitors on the Immune Status Following Surgery in Adult Male Rats
- Author
-
Mohammad Abyari, Samad Alimohammadi, Mehrdad Pooyanmehr, Ali Ghashghaii, and Ali Maleki
- Subjects
surgery ,immune system ,cyclooxygenase inhibitors ,Medicine (General) ,R5-920 ,rat - Abstract
Background and Objectives: Surgery via different mechanisms causes immunosuppression in the postoperative period. The aim of the present study was to investigate the effects of preoperative administration of cyclooxygenase inhibitors on blood levels of Interleukin-2 (IL-2), Interferon-γ (IFN-γ), Tumor Necrosis Factor-α (TNF-α), white blood cells (WBCs) and lymphocytes. Methods: Seventy-five male Wistar rats were divided into five groups (n=15 for each group). Group 1 was gavaged with normal saline for 3 consecutive days without surgery. Group 2 was gavaged with normal saline for 3 consecutive days. Groups 3 to 5 were gavaged with indomethacin (4 mg/kg) and celecoxib (7.5 and 15 mg/kg), respectively, for 3 consecutive days. In Groups 2 to 5, one hour after drugs administration on the third day, laparotomy was used as a surgery pattern. Blood samples were collected 24 hours after surgery and levels IL-2, IFN-γ, TNF-α, WBCs and lymphocytes were determined. Data were analyzed using one-way ANOVA test. Results: Based on the results, a decrease in blood levels of IL-2, IFN-γ and lymphocytes along with an increase in TNF-α and WBCs were observed 24 hours after surgery compared to control rats (P0.05). Also, only celecoxib (15 mg/kg) could decrease the elevated levels TNF-α and WBCs (P
- Published
- 2021
430. Coxibs and Novel Compounds, Chemistry
- Author
-
Laufer, Stefan A., Schmidt, Robert F., editor, and Willis, William D., editor
- Published
- 2007
- Full Text
- View/download PDF
431. NSAIDs and Cardio-Vascular Effects
- Author
-
Brune, Kay, Schmidt, Robert F., editor, and Willis, William D., editor
- Published
- 2007
- Full Text
- View/download PDF
432. NSAIDs and Cancer
- Author
-
Grösch, Sabine, Maier, Thorsten J., Schmidt, Robert F., editor, and Willis, William D., editor
- Published
- 2007
- Full Text
- View/download PDF
433. Bharti Vidyapeeth Deemed University Medical College Researchers Publish New Studies and Findings in the Area of Post-Operative Pain (Efficacy of Celecoxib and Diclofenac Sodium in the Management of Postoperative Pain, Swelling and Mouth Opening...).
- Abstract
Keywords: Analgesics; COX-2 Inhibitors; Celecoxib Therapy; Central Nervous System Agents; Clinical Research; Clinical Trials and Studies; Cyclooxygenase Inhibitors; Diclofenac; Diclofenac Therapy; Drugs and Therapies; Health and Medicine; NSAID; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pharmaceuticals; Phenylacetates; Post-Operative Pain; Surgery EN Analgesics COX-2 Inhibitors Celecoxib Therapy Central Nervous System Agents Clinical Research Clinical Trials and Studies Cyclooxygenase Inhibitors Diclofenac Diclofenac Therapy Drugs and Therapies Health and Medicine NSAID Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pharmaceuticals Phenylacetates Post-Operative Pain Surgery 367 367 1 09/25/23 20230929 NES 230929 2023 SEP 25 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- A new study on post-operative pain is now available. All subjects were randomly allocated to receive one of the following treatments twice a day for five days after surgery: celecoxib 200 mg (n=11) or diclofenac sodium 75 mg (n=10). Analgesics, COX-2 Inhibitors, Celecoxib Therapy, Central Nervous System Agents, Clinical Research, Clinical Trials and Studies, Cyclooxygenase Inhibitors, Diclofenac, Diclofenac Therapy, Drugs and Therapies, Health and Medicine, NSAID, Ophthalmic Antiinflammatory Agents, Ophthalmic Preparations, Pharmaceuticals, Phenylacetates, Post-Operative Pain, Surgery. [Extracted from the article]
- Published
- 2023
434. Jordan University of Science and Technology Researcher Details Findings in Ophthalmic Antiinflammatory Agents (Preclinical comparison of antinociceptive effects between ibuprofen, diclofenac, naproxen, and acetaminophen on acid-stimulated body...).
- Abstract
Keywords: Acetaminophen Therapy; Acetanilides; Analgesic Agents; Anilides; Antiinflammatory Agents; Antinociceptive; Cyclooxygenase Inhibitors; Diclofenac; Diclofenac Therapy; Drugs and Therapies; Health and Medicine; Hydroxy Acids; Ibuprofen Therapy; Lactates; Lactic Acid; NSAID; Naphthaleneacetic Acids; Naproxen; Naproxen Therapy; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pain Medicine; Pharmaceuticals; Phenylacetates; Phenylpropionates EN Acetaminophen Therapy Acetanilides Analgesic Agents Anilides Antiinflammatory Agents Antinociceptive Cyclooxygenase Inhibitors Diclofenac Diclofenac Therapy Drugs and Therapies Health and Medicine Hydroxy Acids Ibuprofen Therapy Lactates Lactic Acid NSAID Naphthaleneacetic Acids Naproxen Naproxen Therapy Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pain Medicine Pharmaceuticals Phenylacetates Phenylpropionates 900 900 1 09/25/23 20230929 NES 230929 2023 SEP 29 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- New research on ophthalmic antiinflammatory agents is the subject of a new report. Acetaminophen Therapy, Acetanilides, Analgesic Agents, Anilides, Antiinflammatory Agents, Antinociceptive, Cyclooxygenase Inhibitors, Diclofenac, Diclofenac Therapy, Drugs and Therapies, Health and Medicine, Hydroxy Acids, Ibuprofen Therapy, Lactates, Lactic Acid, NSAID, Naphthaleneacetic Acids, Naproxen, Naproxen Therapy, Ophthalmic Antiinflammatory Agents, Ophthalmic Preparations, Pain Medicine, Pharmaceuticals, Phenylacetates, Phenylpropionates Keywords for this news article include: Jordan University of Science and Technology, Antinociceptive, Pharmaceuticals, NSAID, Lactates, Lactic Acid, Acetanilides, Hydroxy Acids, Pain Medicine, Phenylacetates, Analgesic Agents, Naproxen Therapy, Ibuprofen Therapy, Phenylpropionates, Diclofenac Therapy, Drugs and Therapies, Health and Medicine, Acetaminophen Therapy, Naphthaleneacetic Acids. [Extracted from the article]
- Published
- 2023
435. Study Findings on Ophthalmic Antiinflammatory Agents Discussed by Researchers at National University of Medical Sciences (NUMS) (Comparison of Analgesic Effect of Intravenous Paracetamol with Intravenous Ketorolac in Patients Presenting With...).
- Abstract
Analgesic Therapy, Analgesics, Antiinflammatory Agents, Central Nervous System Agents, Cyclooxygenase Inhibitors, Drugs and Therapies, Health and Medicine, Ketorolac Therapy, Kidney, Nephrology, Ophthalmic Antiinflammatory Agents, Ophthalmic Preparations, Pain Medicine, Paracetamol Therapy, Pharmaceuticals Keywords: Analgesic Therapy; Analgesics; Antiinflammatory Agents; Central Nervous System Agents; Cyclooxygenase Inhibitors; Drugs and Therapies; Health and Medicine; Ketorolac Therapy; Kidney; Nephrology; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pain Medicine; Paracetamol Therapy; Pharmaceuticals EN Analgesic Therapy Analgesics Antiinflammatory Agents Central Nervous System Agents Cyclooxygenase Inhibitors Drugs and Therapies Health and Medicine Ketorolac Therapy Kidney Nephrology Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pain Medicine Paracetamol Therapy Pharmaceuticals 2220 2220 1 09/25/23 20230929 NES 230929 2023 SEP 29 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- Investigators publish new report on ophthalmic antiinflammatory agents. [Extracted from the article]
- Published
- 2023
436. Study Findings from University of Helsinki Broaden Understanding of Ophthalmic Antiinflammatory Agents (Phytoremediation of Diclofenac Using the Green Liver System: Macrophyte Screening To System Optimization).
- Abstract
Keywords: Lahti; Finland; Europe; Cyclooxygenase Inhibitors; Diclofenac; Diclofenac Therapy; Drugs and Therapies; Health and Medicine; NSAID; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pharmaceuticals; Phenylacetates EN Lahti Finland Europe Cyclooxygenase Inhibitors Diclofenac Diclofenac Therapy Drugs and Therapies Health and Medicine NSAID Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pharmaceuticals Phenylacetates 2187 2187 1 09/25/23 20230929 NES 230929 2023 SEP 29 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Research findings on Drugs and Therapies - Ophthalmic Antiinflammatory Agents are discussed in a new report. Lahti, Finland, Europe, Cyclooxygenase Inhibitors, Diclofenac, Diclofenac Therapy, Drugs and Therapies, Health and Medicine, NSAID, Ophthalmic Antiinflammatory Agents, Ophthalmic Preparations, Pharmaceuticals, Phenylacetates. [Extracted from the article]
- Published
- 2023
437. Findings from Sardar Patel University Yields New Data on Ophthalmic Antiinflammatory Agents [Synthesis and Characterization of Biodegradable Gum Ghatti-cl-poly (Aa-co-nipam)/go Based Hydrogel for Metformin and Sodium Diclofenac Combined Drug...].
- Abstract
Hydrogel was loaded with metformin hydrochloride and sodium diclofenac (DS) as a model drug, and the drugs were released in a pHdependent manner. Keywords: Gujarat; India; Asia; Alcohols; Antidiabetic Agents; Biguanides; Cyclooxygenase Inhibitors; Diclofenac; Diclofenac Therapy; Drug Delivery; Drug Delivery Systems; Drugs and Therapies; Health and Medicine; Hydrogel; Hypoglycemic Agents; Metformin; Metformin Therapy; NSAID; Non-Sulfonylureas; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Organic Chemicals; Pharmaceuticals; Phenylacetates; Polyethylene Glycols EN Gujarat India Asia Alcohols Antidiabetic Agents Biguanides Cyclooxygenase Inhibitors Diclofenac Diclofenac Therapy Drug Delivery Drug Delivery Systems Drugs and Therapies Health and Medicine Hydrogel Hypoglycemic Agents Metformin Metformin Therapy NSAID Non-Sulfonylureas Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Organic Chemicals Pharmaceuticals Phenylacetates Polyethylene Glycols 703 703 1 09/25/23 20230929 NES 230929 2023 SEP 29 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on Drugs and Therapies - Ophthalmic Antiinflammatory Agents have been published. [Extracted from the article]
- Published
- 2023
438. Researcher from Shaare Zedek Medical Center Details Findings in Heart Disease (Simultaneous multifocal intracranial haemorrhages associated with staphylococcus aureus endocarditis: a plausible role for diclofenac administration).
- Abstract
Bacillales, Cardiology, Cardiovascular Diseases and Conditions, Cyclooxygenase Inhibitors, Diclofenac, Diclofenac Therapy, Drugs and Therapies, Endocarditis, Endospore-Forming Bacteria, Gram-Positive Bacteria, Gram-Positive Cocci, Gram-Positive Endospore-Forming Rods, Health and Medicine, Heart Disease, Heart Disorders and Diseases, NSAID, Ophthalmic Antiinflammatory Agents, Ophthalmic Preparations, Pharmaceuticals, Phenylacetates, Staphylococcaceae, Staphylococcus, Staphylococcus aureus Keywords: Bacillales; Cardiology; Cardiovascular Diseases and Conditions; Cyclooxygenase Inhibitors; Diclofenac; Diclofenac Therapy; Drugs and Therapies; Endocarditis; Endospore-Forming Bacteria; Gram-Positive Bacteria; Gram-Positive Cocci; Gram-Positive Endospore-Forming Rods; Health and Medicine; Heart Disease; Heart Disorders and Diseases; NSAID; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pharmaceuticals; Phenylacetates; Staphylococcaceae; Staphylococcus; Staphylococcus aureus EN Bacillales Cardiology Cardiovascular Diseases and Conditions Cyclooxygenase Inhibitors Diclofenac Diclofenac Therapy Drugs and Therapies Endocarditis Endospore-Forming Bacteria Gram-Positive Bacteria Gram-Positive Cocci Gram-Positive Endospore-Forming Rods Health and Medicine Heart Disease Heart Disorders and Diseases NSAID Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pharmaceuticals Phenylacetates Staphylococcaceae Staphylococcus Staphylococcus aureus 708 708 1 09/25/23 20230925 NES 230925 2023 SEP 25 (NewsRx) -- By a News Reporter-Staff News Editor at Heart Disease Weekly -- Fresh data on heart disease are presented in a new report. [Extracted from the article]
- Published
- 2023
439. Patent Issued for Compounded compositions and methods for treating pain (USPTO 11737975).
- Published
- 2023
440. Data on Ophthalmic Antiinflammatory Agents Detailed by a Researcher at McGovern Medical School at the University of Texas Health Science Center (The Limit Is Zero: A Prospective Evaluation of Ketorolac in Patients Undergoing Primary...).
- Abstract
Keywords: Antiinflammatory Agents; Cyclooxygenase Inhibitors; Drugs and Therapies; Health and Medicine; Ketorolac Therapy; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pharmaceuticals; Surgery EN Antiinflammatory Agents Cyclooxygenase Inhibitors Drugs and Therapies Health and Medicine Ketorolac Therapy Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pharmaceuticals Surgery 400 400 1 09/19/23 20230922 NES 230922 2023 SEP 22 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- A new study on ophthalmic antiinflammatory agents is now available. Antiinflammatory Agents, Cyclooxygenase Inhibitors, Drugs and Therapies, Health and Medicine, Ketorolac Therapy, Ophthalmic Antiinflammatory Agents, Ophthalmic Preparations, Pharmaceuticals, Surgery. [Extracted from the article]
- Published
- 2023
441. Researchers from Lomonosov Moscow State University Describe Findings in Ophthalmic Antiinflammatory Agents (Boron Subphthalocyanines Bearing Non-steroidal Anti-inflammatory Drug Diclofenac: Synthesis and Photochemical Properties).
- Abstract
Keywords: Moscow; Russia; Boron; Cyclooxygenase Inhibitors; Diclofenac; Diclofenac Therapy; Drugs and Therapies; Health and Medicine; NSAID; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pharmaceuticals; Phenylacetates EN Moscow Russia Boron Cyclooxygenase Inhibitors Diclofenac Diclofenac Therapy Drugs and Therapies Health and Medicine NSAID Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pharmaceuticals Phenylacetates 1932 1932 1 09/19/23 20230922 NES 230922 2023 SEP 22 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New research on Drugs and Therapies - Ophthalmic Antiinflammatory Agents is the subject of a report. Moscow, Russia, Boron, Cyclooxygenase Inhibitors, Diclofenac, Diclofenac Therapy, Drugs and Therapies, Health and Medicine, NSAID, Ophthalmic Antiinflammatory Agents, Ophthalmic Preparations, Pharmaceuticals, Phenylacetates. [Extracted from the article]
- Published
- 2023
442. Recent Findings from National Institute of Technology Karnataka Provides New Insights into Ophthalmic Antiinflammatory Agents (Functionalization of Beta-cyclodextrin Onto Nife2o4 Nanoparticles for the Removal of Ketoprofen and Diclofenac From...).
- Published
- 2023
443. Maria Curie-Sklodowska University Researcher Highlights Recent Research in Ophthalmic Antiinflammatory Agents (Synthesis and Characterization of Agarose Hydrogels for Release of Diclofenac Sodium).
- Abstract
The news reporters obtained a quote from the research from Maria Curie-Sklodowska University: "Among them, agarose-based hydrogels are an interesting, but still not fully explored, group of potential platforms for controlled drug release. Keywords: Cyclooxygenase Inhibitors; Diclofenac; Diclofenac Therapy; Drugs and Therapies; Health and Medicine; NSAID; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pharmaceuticals; Phenylacetates EN Cyclooxygenase Inhibitors Diclofenac Diclofenac Therapy Drugs and Therapies Health and Medicine NSAID Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pharmaceuticals Phenylacetates 874 874 1 09/19/23 20230922 NES 230922 2023 SEP 22 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New study results on ophthalmic antiinflammatory agents have been published. [Extracted from the article]
- Published
- 2023
444. New Findings in Ophthalmic Antiinflammatory Agents Described from Orthopedic Department (Treatment Satisfaction, Efficacy, and Tolerability of Low-Dose Diclofenac Epolamine Soft Capsules in Acute, Mild, or Moderate Musculoskeletal Pain: A...).
- Abstract
Keywords: Analgesic Therapy; Analgesics; Central Nervous System Agents; Cyclooxygenase Inhibitors; Diclofenac; Diclofenac Therapy; Drugs and Therapies; Health and Medicine; NSAID; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pain Management; Pain Medicine; Pharmaceuticals; Phenylacetates EN Analgesic Therapy Analgesics Central Nervous System Agents Cyclooxygenase Inhibitors Diclofenac Diclofenac Therapy Drugs and Therapies Health and Medicine NSAID Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pain Management Pain Medicine Pharmaceuticals Phenylacetates 1231 1231 1 09/11/23 20230915 NES 230915 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Pain & Central Nervous System Week -- New study results on ophthalmic antiinflammatory agents have been published. Analgesic Therapy, Analgesics, Central Nervous System Agents, Cyclooxygenase Inhibitors, Diclofenac, Diclofenac Therapy, Drugs and Therapies, Health and Medicine, NSAID, Ophthalmic Antiinflammatory Agents, Ophthalmic Preparations, Pain Management, Pain Medicine, Pharmaceuticals, Phenylacetates. [Extracted from the article]
- Published
- 2023
445. Reports Summarize Ophthalmic Antiinflammatory Agents Study Results from Department of Veterinary Physiology and Biochemistry (Therapeutic effects of hydroethanolic extract of Erythrina senegalensis in diclofenac sodium-induced hepatotoxicity in...).
- Abstract
For more information on this research see: Therapeutic effects of hydroethanolic extract of Erythrina senegalensis in diclofenac sodium-induced hepatotoxicity in male Wistar rat: biochemical, redox potential and histopathological outcomes. Keywords: Biochemicals; Biochemistry; Chemicals; Cyclooxygenase Inhibitors; Diclofenac; Diclofenac Therapy; Drugs and Therapies; Gastroenterology; Glutathione; Health and Medicine; NSAID; Oligopeptides; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Peptides; Pharmaceuticals; Phenylacetates EN Biochemicals Biochemistry Chemicals Cyclooxygenase Inhibitors Diclofenac Diclofenac Therapy Drugs and Therapies Gastroenterology Glutathione Health and Medicine NSAID Oligopeptides Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Peptides Pharmaceuticals Phenylacetates 2221 2221 1 09/11/23 20230915 NES 230915 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Fresh data on ophthalmic antiinflammatory agents are presented in a new report. [Extracted from the article]
- Published
- 2023
446. Researchers from University of Lorraine Discuss Research in Ophthalmic Antiinflammatory Agents (Enhanced Diclofenac Photomineralization under Solar Light Using Ce [ [1-x] ] Zn [ [x] ] O [ [2-x] ] Solid Solution Catalysts: Synergistic Effect of...).
- Abstract
Moreover, the results indicate that the coexistence of Zn SP 2+ sp and Ce SP 4+ sp and the oxygen vacancies rate in CeZnx solid solution are key factors for strong drug mineralization." Keywords: Chalcogens; Cyclooxygenase Inhibitors; Diclofenac; Diclofenac Therapy; Drugs and Therapies; Health and Medicine; NSAID; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pharmaceuticals; Phenylacetates EN Chalcogens Cyclooxygenase Inhibitors Diclofenac Diclofenac Therapy Drugs and Therapies Health and Medicine NSAID Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pharmaceuticals Phenylacetates 2906 2906 1 09/11/23 20230915 NES 230915 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Researchers detail new data in ophthalmic antiinflammatory agents. Chalcogens, Cyclooxygenase Inhibitors, Diclofenac, Diclofenac Therapy, Drugs and Therapies, Health and Medicine, NSAID, Ophthalmic Antiinflammatory Agents, Ophthalmic Preparations, Pharmaceuticals, Phenylacetates. [Extracted from the article]
- Published
- 2023
447. Research Results from Henan Normal University Update Understanding of Ophthalmic Antiinflammatory Agents (A Carboxyl Group-Functionalized Ionic Liquid Hybrid Adsorbent for Solid-Phase Extraction and Determination of Trace Diclofenac Sodium in...).
- Abstract
Keywords for this news article include: Henan Normal University, Pharmaceuticals, NSAID, Solvents, Ionic Liquids, Phenylacetates, Diclofenac Therapy, Drugs and Therapies, Health and Medicine, Ophthalmic Preparations, Cyclooxygenase Inhibitors, Ophthalmic Antiinflammatory Agents. Cyclooxygenase Inhibitors, Diclofenac, Diclofenac Therapy, Drugs and Therapies, Health and Medicine, Ionic Liquids, NSAID, Ophthalmic Antiinflammatory Agents, Ophthalmic Preparations, Pharmaceuticals, Phenylacetates, Solvents Keywords: Cyclooxygenase Inhibitors; Diclofenac; Diclofenac Therapy; Drugs and Therapies; Health and Medicine; Ionic Liquids; NSAID; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pharmaceuticals; Phenylacetates; Solvents EN Cyclooxygenase Inhibitors Diclofenac Diclofenac Therapy Drugs and Therapies Health and Medicine Ionic Liquids NSAID Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pharmaceuticals Phenylacetates Solvents 2420 2420 1 09/11/23 20230915 NES 230915 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on ophthalmic antiinflammatory agents. [Extracted from the article]
- Published
- 2023
448. Researchers from National Polytechnic Institute Describe Findings in Ophthalmic Antiinflammatory Agents [Al(Iii)-based Mofs Adsorbent for Pollution Remediation: Insights Into Selective Adsorption of Sodium Diclofenac].
- Abstract
Keywords: Ciudad de Mexico; Mexico; North and Central America; Cyclooxygenase Inhibitors; Diclofenac; Diclofenac Therapy; Drugs and Therapies; Health and Medicine; NSAID; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pharmaceuticals; Phenylacetates EN Ciudad de Mexico Mexico North and Central America Cyclooxygenase Inhibitors Diclofenac Diclofenac Therapy Drugs and Therapies Health and Medicine NSAID Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pharmaceuticals Phenylacetates 2839 2839 1 09/11/23 20230915 NES 230915 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Current study results on Drugs and Therapies - Ophthalmic Antiinflammatory Agents have been published. Keywords for this news article include: Ciudad de Mexico, Mexico, North and Central America, Cyclooxygenase Inhibitors, Diclofenac, Diclofenac Therapy, Drugs and Therapies, Health and Medicine, NSAID, Ophthalmic Antiinflammatory Agents, Ophthalmic Preparations, Pharmaceuticals, Phenylacetates, National Polytechnic Institute. According to news reporting originating from Ciudad de Mexico, Mexico, by NewsRx correspondents, research stated, "The presence and persistence of pharmaceuticals in water affect human health, causing drug resistance and adverse effects on aquatic life. [Extracted from the article]
- Published
- 2023
449. Data on Ophthalmic Antiinflammatory Agents Discussed by a Researcher at American University (Polypyrrole- and Polyaniline-Coated Cotton Fabrics as Efficient Adsorbents for the Pharmaceutical Water Contaminants Diclofenac and Salicylic Acid).
- Abstract
Keywords: Benzoic Acids; Carboxylic Acids; Cyclooxygenase Inhibitors; Dermatological Agents; Diclofenac; Diclofenac Therapy; Drugs and Therapies; Health and Medicine; Hydroxy Acids; Hydroxybenzoic Acids; NSAID; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Organic Chemicals; Pharmaceuticals; Phenylacetates; Salicylic Acid Therapy; Salicylic Acids; Topical Acne Agents; Topical Agents EN Benzoic Acids Carboxylic Acids Cyclooxygenase Inhibitors Dermatological Agents Diclofenac Diclofenac Therapy Drugs and Therapies Health and Medicine Hydroxy Acids Hydroxybenzoic Acids NSAID Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Organic Chemicals Pharmaceuticals Phenylacetates Salicylic Acid Therapy Salicylic Acids Topical Acne Agents Topical Agents 649 649 1 09/11/23 20230915 NES 230915 2023 SEP 15 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- Data detailed on ophthalmic antiinflammatory agents have been presented. The best adsorption performance for both contaminants was shown on the PPY-coated fabrics, which yielded adsorption capacities of about 65 and 21 mg/g for DCF and SA, respectively. [Extracted from the article]
- Published
- 2023
450. Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease : Monocentric Study, Controlled, Randomized, Partially Blinded, in Paralleled Groups.
- Subjects
DE Quervain disease ,ECZEMA ,TENOSYNOVITIS ,AROMATHERAPY ,PATIENTS - Abstract
Keywords: Aromatherapy; Clinical Research; Clinical Trials and Studies; Complementary and Alternative Medicine; Consumer Electronics; Corticosteroids; Cyclooxygenase Inhibitors; De Quervain Disease; Diclofenac Therapy; Drugs and Therapies; Electronics; Health and Medicine; Hospitals; Inflammation; Mind-Body Therapy; Muscular Diseases and Conditions; Musculoskeletal Diseases and Conditions; Musculoskeletal Diseases and Conditions - De Quervain Disease; NSAID; Ophthalmic Antiinflammatory Agents; Ophthalmic Preparations; Pathology; Pharmaceuticals; Sensory Art Therapy; Tendinopathy; Tendon Entrapment; Tenosynovitis; Therapy; Video Game EN Aromatherapy Clinical Research Clinical Trials and Studies Complementary and Alternative Medicine Consumer Electronics Corticosteroids Cyclooxygenase Inhibitors De Quervain Disease Diclofenac Therapy Drugs and Therapies Electronics Health and Medicine Hospitals Inflammation Mind-Body Therapy Muscular Diseases and Conditions Musculoskeletal Diseases and Conditions Musculoskeletal Diseases and Conditions - De Quervain Disease NSAID Ophthalmic Antiinflammatory Agents Ophthalmic Preparations Pathology Pharmaceuticals Sensory Art Therapy Tendinopathy Tendon Entrapment Tenosynovitis Therapy Video Game 953 953 1 09/11/23 20230911 NES 230911 2023 SEP 11 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Staff editors report on the newly launched clinical trial, NCT06012097, which has the following summary description: "De Quervain disease is characterized by an adductor pollicis longus and extensor pollicis brevis tendons inflammation as thys pass beneath the extensor retinaculum at the radial styloid. Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease: Monocentric Study, Controlled, Randomized, Partially Blinded, in Paralleled Groups Currently, the treatment is mainly conservative by splint and anti-inflammatory gel and/or corticosteroid infiltration. [Extracted from the article]
- Published
- 2023
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.